Literature DB >> 25427930

Oral everolimus treatment in a preterm infant with multifocal inoperable cardiac rhabdomyoma associated with tuberous sclerosis complex and a structural heart defect.

Ibrahim Mohamed1, Guillaume Ethier1, Isabelle Goyer1, Philippe Major2, Nagib Dahdah2.   

Abstract

Rhabdomyoma (RHM) is a benign cardiac tumour usually associated with tuberous sclerosis complex (TSC). Most RHMs are asymptomatic and regress spontaneously during the first years of life. Haemodynamically significant RHMs are classically treated with surgical excision. We present a case of a premature infant, born to a mother having TSC, with a prenatal diagnosis of pulmonary valve atresia and a large ventricular septal defect. Multiple cardiac RHMs were also present, including a large tumour affecting the right ventricular filling. Owing to the prematurity and low birth weight, the infant was inoperable. In this report, we describe our approach to pharmacologically reduce the RHM size using oral everolimus in preparation for a two-ventricle surgical repair of the structural cardiac defect. We also specifically describe the dose of everolimus that was used in this case to achieve therapeutic serum levels, which was seven times lower than the conventional dose applicable for older infants. 2014 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25427930      PMCID: PMC4248106          DOI: 10.1136/bcr-2014-205138

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  19 in total

1.  Fetal cardiac tumors: a single-center experience of 40 cases.

Authors:  Yoav Yinon; David Chitayat; Susan Blaser; Mike Seed; Hagai Amsalem; Shi-Joon Yoo; Edgar T Jaeggi
Journal:  Prenat Diagn       Date:  2010-10       Impact factor: 3.050

Review 2.  Tuberous sclerosis complex: tumors and tumorigenesis.

Authors:  Julita Borkowska; Robert A Schwartz; Katarzyna Kotulska; Sergiusz Jozwiak
Journal:  Int J Dermatol       Date:  2011-01       Impact factor: 2.736

3.  Prenatal diagnosis of giant cardiac rhabdomyoma with fetal hydrops in tuberous sclerosis.

Authors:  Frederike Schlaegel; Zoltan Takacs; Erich Franz Solomayer; Hashim Abdul-Kaliq; Gabriele Meyberg-Solomayer
Journal:  J Prenat Med       Date:  2013-07

4.  Regression of a cardiac rhabdomyoma in a patient receiving everolimus.

Authors:  Dana Tiberio; David N Franz; John R Phillips
Journal:  Pediatrics       Date:  2011-04-04       Impact factor: 7.124

5.  Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation.

Authors:  Jennifer A Chan; Hongbing Zhang; Penelope S Roberts; Sergiusz Jozwiak; Grajkowska Wieslawa; Joanna Lewin-Kowalik; Katarzyna Kotulska; David J Kwiatkowski
Journal:  J Neuropathol Exp Neurol       Date:  2004-12       Impact factor: 3.685

6.  Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis.

Authors:  Dan Ehninger; Sangyeul Han; Carrie Shilyansky; Yu Zhou; Weidong Li; David J Kwiatkowski; Vijaya Ramesh; Alcino J Silva
Journal:  Nat Med       Date:  2008-06-22       Impact factor: 53.440

Review 7.  Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies.

Authors:  Michael Wong
Journal:  Epilepsia       Date:  2009-10-08       Impact factor: 5.864

Review 8.  The TSC1-TSC2 complex: a molecular switchboard controlling cell growth.

Authors:  Jingxiang Huang; Brendan D Manning
Journal:  Biochem J       Date:  2008-06-01       Impact factor: 3.857

9.  Diagnosis and management of fetal cardiac tumors: a multicenter experience and review of published reports.

Authors:  D G Holley; G R Martin; J I Brenner; D A Fyfe; J C Huhta; C S Kleinman; S B Ritter; N H Silverman
Journal:  J Am Coll Cardiol       Date:  1995-08       Impact factor: 24.094

Review 10.  Outcome of antenatally diagnosed cardiac rhabdomyoma: case series and a meta-analysis.

Authors:  A S Chao; A Chao; T H Wang; Y C Chang; Y L Chang; C C Hsieh; R Lien; W J Su
Journal:  Ultrasound Obstet Gynecol       Date:  2008-03       Impact factor: 7.299

View more
  6 in total

1.  Accelerated Cardiac Rhabdomyoma Regression with Everolimus in Infants with Tuberous Sclerosis Complex.

Authors:  Fatou Aw; Isabelle Goyer; Marie-Josée Raboisson; Christine Boutin; Philippe Major; Nagib Dahdah
Journal:  Pediatr Cardiol       Date:  2016-11-23       Impact factor: 1.655

2.  Innovative Strategies for the Management of a Massive Neonatal Rhabdomyoma.

Authors:  N Prabhu; N Osifodunrin; D Murphy; S Butler; L E Hunter
Journal:  J Pediatr Intensive Care       Date:  2017-09-12

3.  Symptomatic improvement using everolimus in infants with cardiac rhabdomyoma.

Authors:  Bhargavi Dhulipudi; Shweta Bhakru; Saileela Rajan; Vinoth Doraiswamy; Nageswara Rao Koneti
Journal:  Ann Pediatr Cardiol       Date:  2019 Jan-Apr

Review 4.  Treatment of Cardiac Rhabdomyomas with mTOR Inhibitors in Children with Tuberous Sclerosis Complex-A Systematic Review.

Authors:  Monika Sugalska; Anna Tomik; Sergiusz Jóźwiak; Bożena Werner
Journal:  Int J Environ Res Public Health       Date:  2021-05-05       Impact factor: 3.390

5.  Massive biventricular rhabdomyoma in a neonate.

Authors:  Manish Pandey; Rimlee Dutta; Shyam S Kothari
Journal:  Ann Pediatr Cardiol       Date:  2017 May-Aug

6.  Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age - a multicenter retrospective study.

Authors:  Afshin Saffari; Ines Brösse; Adelheid Wiemer-Kruel; Bernd Wilken; Paula Kreuzaler; Andreas Hahn; Matthias K Bernhard; Cornelis M van Tilburg; Georg F Hoffmann; Matthias Gorenflo; Sven Hethey; Olaf Kaiser; Stefan Kölker; Robert Wagner; Olaf Witt; Andreas Merkenschlager; Andreas Möckel; Timo Roser; Jan-Ulrich Schlump; Antje Serfling; Juliane Spiegler; Till Milde; Andreas Ziegler; Steffen Syrbe
Journal:  Orphanet J Rare Dis       Date:  2019-05-03       Impact factor: 4.123

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.